Results 201 to 210 of about 1,459,532 (261)

Height Velocity in Pediatric Cystic Fibrosis Under Triple CFTR Modulator Therapy: A Real-Life Monocentric Experience. [PDF]

J Clin Med
Boni A, d'Aniello F, Ubertini G, Cappa M, Ciciriello F, Majo F, Cristiani L, Alghisi F, Montemitro E, Bella S, De Marchis M, Cutrera R, Fiocchi AG.   +12 more
europepmc   +1 more source

Relationship between skeletal muscle indicators and clinical outcomes in cystic fibrosis is modified by adiposity and CFTR modulator use: a cross-sectional analysis. [PDF]

Am J Clin Nutr
Gonzalez Ramirez LA, Suppakitjanusant P, Burley TM, Zaveri S, Stecenko AA, Hunt WR, Harris RA, Stallings VA, Ivie EA, Driggers C, Binongo JN, Ziegler TR, Alvarez JA.   +12 more
europepmc   +1 more source

Building Lay Society Knowledge and Education for Health Technology Assessment and Policy Engagement: Case of CFTR Modulator Access in Brazil. [PDF]

Healthcare (Basel)
de Oliveira VSB, Amaral MB, Camargo M, Lopes-Pacheco M.   +3 more
europepmc   +1 more source

Personalised CFTR Modulator Treatment Initiation and Monitoring in CF-Related Liver Disease: When Less Is More. [PDF]

Respirol Case Rep
Vekaria S, Kavanagh G, Mulrennan S.
europepmc   +1 more source

Innate Immunity in Cystic Fibrosis: Varied Effects of CFTR Modulator Therapy on Cell-to-Cell Communication. [PDF]

Int J Mol Sci
Hynes J, Taggart CC, Tirouvanziam R, Coppinger JA.   +3 more
europepmc   +1 more source

Preservation of β-cell Function in Pancreatic Insufficient Cystic Fibrosis With Highly Effective CFTR Modulator Therapy.

J Clin Endocrinol Metab, 2023
Flatt AJ, Sheikh S, Peleckis AJ, Alvarado P, Hadjiliadis D, Stefanovski D, Gallop RJ, Rubenstein RC, Kelly A, Rickels MR.   +9 more
europepmc   +1 more source

Kidney effects of triple CFTR modulator therapy in people with cystic fibrosis. [PDF]

Clin Kidney J
Gabai P, Novel-Catin E, Reynaud Q, Nove-Josserand R, Pelletier S, Fouque D, Koppe L, Durieu I.   +7 more
europepmc   +1 more source

CFTR Modulator Therapy in the Treatment of Cystic Fibrosis as Compared to Placebo

Objective: To assess the efficacy of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies including ivacaftor, tezacaftor/ivacaftor, and elexacaftor/tezacaftor/ivacaftor combinations in the improvement of lung function in ...
Doody, Rebecca
core  

Pancreatic, nutritional and clinical outcomes in children 0-5 years with cystic fibrosis during the first 2 years of CFTR modulator therapy (PaNC): a multicentre prospective observational study protocol. [PDF]

BMJ Open
Miles C, Katz T, Grunert J, Ford K, Hall C, Hawthorn C, See DW, McMahon M, Vass H, Watkins S, Zanardo G, Brookes I, Handley S, Woodward T, Wademan J, Cameron B, King S, Nixon GM, Davidson Z.   +18 more
europepmc   +1 more source

The effect of triple CFTR modulator therapy and azithromycin on ion channels and inflammation in cystic fibrosis. [PDF]

ERJ Open Res
Bani Melhim S, Douglas LEJ, Reihill JA, Downey DG, Martin SL.   +4 more
europepmc   +1 more source